International Journal of Pathology Sciences

ISSN Print: 2664-9063
ISSN Online: 2664-9071
IJPS 2024; 6(1): 31-35
www.pathologyjournal.net
Received: 02-07-2024
Accepted: 05-08-2024

Dr. Andrew Kabugo
Department of Pathology, Makerere University, Kampala, Uganda

Corresponding Author:
Dr. Andrew Kabugo
Department of Pathology, Makerere University, Kampala, Uganda

Molecular pathology in the diagnosis and classification of soft tissue sarcomas

Dr. Andrew Kabugo

DOI: https://doi.org/10.33545/26649063.2024.v6.i1a.19

Abstract
Soft tissue sarcomas (STS) are a diverse group of malignancies originating from mesenchymal tissues. The accurate diagnosis and classification of these tumors are critical for determining appropriate treatment strategies and prognostic outcomes. Molecular pathology has emerged as a pivotal tool in enhancing the diagnostic precision of STS, complementing traditional histopathological methods. This paper reviews the molecular techniques used in the diagnosis and classification of soft tissue sarcomas, including cytogenetic analysis, fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), and next-generation sequencing (NGS). It also discusses the implications of molecular findings in the context of personalized medicine.

Keywords: Soft tissue sarcomas, molecular pathology, diagnosis and classification

Introduction
Soft tissue sarcomas (STS) are a diverse and complex group of malignant tumors arising from mesenchymal tissues, including fat, muscle, nerves, and blood vessels. With over 50 distinct histological subtypes, STS represents a significant challenge in clinical oncology, particularly in terms of accurate diagnosis and classification. The rarity and heterogeneity of these tumors compound the difficulties, leading to potential misdiagnoses that can adversely affect treatment strategies and patient outcomes. Historically, the diagnosis of STS has relied heavily on traditional histopathological methods, which involve the microscopic examination of tissue samples to identify morphological features characteristic of different tumor types. While histopathology remains a cornerstone in the diagnosis of STS, it has limitations, particularly when distinguishing between morphologically similar subtypes. For instance, liposarcomas and benign lipomas can appear strikingly similar under the microscope, making it difficult to accurately diagnose without additional molecular information. This diagnostic ambiguity has been a critical issue in the management of STS, as the treatment approaches and prognoses for different subtypes can vary significantly. The advent of molecular pathology has brought about a paradigm shift in the diagnosis and classification of STS. Molecular pathology involves the analysis of genetic alterations within tumors, providing insights that are not discernible through conventional histopathology alone. Studies have shown that specific genetic changes, such as chromosomal translocations, gene fusions, and point mutations, are often pathognomonic for certain subtypes of STS. For example, the identification of the EWSR1-FLI1 fusion gene, resulting from the t(11; 22) (q24;q12) translocation, has been established as a definitive marker for Ewing sarcoma. Similarly, the detection of the SS18-SSX fusion gene, arising from the t(X; 18) (p11; q11) translocation, is crucial for diagnosing synovial sarcoma. These molecular markers not only enhance diagnostic accuracy but also provide valuable prognostic information and guide therapeutic decisions. Several studies have demonstrated the impact of molecular techniques on improving the accuracy of STS diagnosis. For instance, cytogenetic analysis, which involves the study of chromosomes in tumor cells, has been instrumental in identifying characteristic chromosomal translocations in various STS subtypes. Fluorescence in situ hybridization (FISH) and reverse transcription polymerase chain reaction (RT-PCR) are commonly used to

detect specific gene fusions associated with these translocations. Moreover, the advent of next-generation sequencing (NGS) has revolutionized the field by allowing the simultaneous analysis of multiple genes, uncovering a wide range of genetic alterations that may be relevant to the diagnosis and treatment of STS. NGS provides a comprehensive molecular profile of the tumor, which can reveal actionable mutations that may be targeted by existing or experimental therapies. Data from previous research underscore the significance of molecular pathology in STS management. For example, a study on gastrointestinal stromal tumors (GISTs) highlighted the importance of identifying mutations in the KIT or PDGFRA genes, which not only confirm the diagnosis but also predict response to tyrosine kinase inhibitors like imatinib. Patients with specific KIT mutations have been shown to benefit from targeted therapy, which has dramatically improved survival rates compared to traditional chemotherapy. Similarly, the identification of MDM2 and CDK4 gene amplifications in well-differentiated liposarcoma has provided a clear distinction from benign lipomas, leading to more appropriate treatment strategies. Despite these advancements, challenges remain in the implementation of molecular pathology in routine clinical practice. The rarity of certain STS subtypes and the variability in the availability of molecular diagnostic tools across different healthcare settings can limit the widespread adoption of these techniques. Additionally, the interpretation of molecular data requires specialized expertise, and there is a need for standardized guidelines to ensure consistency in diagnosis and reporting. In conclusion, molecular pathology has emerged as a critical component in the diagnosis and classification of soft tissue sarcomas. By complementing traditional histopathology, molecular techniques offer a higher level of diagnostic precision, enabling the identification of specific genetic alterations that define different STS subtypes. As the field of personalized medicine continues to evolve, the integration of molecular pathology into clinical practice holds the promise of improved treatment outcomes for patients with these challenging malignancies. Further research and the development of standardized protocols are essential to fully realize the potential of molecular diagnostics in the management of STS.

Main Objective

The main objective of this study is to evaluate the role of molecular pathology in the accurate diagnosis and classification of soft tissue sarcomas (STS), with a focus on how molecular techniques, such as cytogenetic analysis, fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), and next-generation sequencing (NGS), enhance diagnostic precision, guide therapeutic decisions, and improve prognostic outcomes in the context of personalized medicine.

The Role of Molecular Pathology in STS Diagnosis

Molecular pathology has become a critical aspect of diagnosing and classifying soft tissue sarcomas (STS), offering a level of precision that was previously unattainable with traditional histopathology alone. This field focuses on the identification of specific genetic alterations that characterize different subtypes of STS, thus enhancing diagnostic accuracy, guiding therapeutic decisions, and providing prognostic insights. The role of molecular pathology in STS diagnosis can be understood through its ability to detect genetic abnormalities, such as chromosomal translocations, gene fusions, mutations, and amplifications, which are often pathognomonic for certain sarcomas.

Molecular Pathology in STS diagnosis



One of the significant advancements in molecular pathology is the detection of chromosomal translocations, which are common in several STS subtypes. For example, the t(11;22)(q24;q12) translocation, which results in the EWSR1-FLI1 fusion gene, is a hallmark of Ewing sarcoma. The identification of this translocation through techniques like fluorescence in situ hybridization (FISH) or reverse transcription polymerase chain reaction (RT-PCR) has made it possible to diagnose Ewing sarcoma with high specificity, even when histopathological features are ambiguous. Similarly, the detection of the SS18-SSX fusion gene resulting from the t(X; 18) (p11; q11) translocation is crucial in diagnosing synovial sarcoma, another subtype where histological overlap with other spindle cell tumors can lead to diagnostic challenges. Molecular pathology also plays a vital role in the sub-classification of STS, which is increasingly important in the era of personalized medicine. For instance, gastrointestinal stromal tumors (GISTs) are primarily driven by mutations in the KIT or PDGFRA genes. The identification of these mutations not only confirms the diagnosis but also informs treatment decisions, as patients with specific KIT mutations respond well to tyrosine kinase inhibitors like imatinib. This level of precision in diagnosis and treatment contrasts sharply with earlier methods, where such targeted therapies were not available, and treatments were more generalized, often leading to suboptimal outcomes. In recent years, next-generation sequencing (NGS) has emerged as a powerful tool in the molecular pathology of STS. NGS allows for the simultaneous analysis of multiple genes, uncovering a broad spectrum of genetic alterations, including those that are rare or novel. This comprehensive approach contrasts with traditional single-gene tests, which are more limited in scope. NGS provides a detailed molecular profile of the tumor, which can reveal actionable mutations that may be targeted by existing or experimental therapies. This capability represents a significant advancement over previous diagnostic methods, which could not capture the full complexity of the tumor's genetic landscape. Comparatively, earlier studies on STS diagnosis relied heavily on histopathological examination, which, while essential, often struggled with the significant morphological

overlap between different sarcoma subtypes. These studies highlighted the limitations of histopathology, particularly in distinguishing between morphologically similar but genetically distinct tumors. For example, distinguishing between liposarcoma subtypes was particularly challenging before the advent of molecular techniques. Well-differentiated liposarcoma and benign lipoma, for instance, can appear very similar under the microscope, but molecular pathology allows for the detection of MDM2 and CDK4 gene amplifications, which are present in well-differentiated liposarcoma but absent in benign lipomas. This molecular distinction is crucial, as it significantly impacts treatment decisions and prognostication. Moreover, the evolution of molecular pathology has addressed some of the diagnostic uncertainties and inconsistencies noted in previous studies. Historically, the diagnosis of STS was fraught with challenges due to the rarity and heterogeneity of these tumors. Misdiagnosis was not uncommon, leading to inappropriate treatment strategies. Earlier research often emphasized the need for more reliable diagnostic markers, and molecular pathology has fulfilled this need by providing specific genetic signatures that correlate with distinct STS subtypes. In comparing current molecular pathology practices with previous diagnostic approaches, the most notable improvement is the precision and specificity that molecular techniques offer. While traditional methods relied on morphological and immunohistochemical characteristics, which could sometimes be subjective, molecular pathology provides objective data based on genetic alterations. This shift from a morphology-based to a genetics-based approach represents a paradigm change in the diagnosis and management of STS. Furthermore, molecular pathology has enhanced our understanding of the biology of STS, revealing insights into tumor behavior, metastatic potential, and response to therapy. This knowledge was less accessible in the past when diagnosis was primarily based on histopathology. For example, understanding the role of secondary mutations in resistance to therapy, as seen in GISTs treated with imatinib, was only possible through molecular studies that identified these mutations. Such insights have led to the development of second-line therapies, offering hope to patients who would have otherwise exhausted their treatment options.

Molecular Subtypes and Clinical Implications

Molecular subtyping has become a cornerstone in the diagnosis and management of soft tissue sarcomas (STS), offering profound insights into the biological behavior of these tumors and their clinical implications. The identification of specific genetic alterations has not only facilitated more accurate diagnosis but has also paved the way for personalized treatment approaches tailored to the molecular characteristics of each subtype. This shift towards a molecularly informed understanding of STS has led to significant improvements in patient outcomes, particularly in terms of targeted therapies and prognostication.

One of the well-characterized molecular subtypes of STS is gastrointestinal stromal tumors (GISTs), which are primarily driven by mutations in the KIT and PDGFRA genes. Approximately 85% of GISTs harbor mutations in the KIT gene, while another 5-7% possess mutations in the PDGFRA gene. These mutations lead to constitutive activation of receptor tyrosine kinases, which promotes uncontrolled cell proliferation. The discovery of these mutations has had profound clinical implications, as it has directly led to the development and use of tyrosine kinase inhibitors (TKIs) such as imatinib. Imatinib has shown remarkable efficacy in treating GISTs with KIT mutations, with studies demonstrating response rates of up to 80%. This represents a dramatic improvement over conventional chemotherapy, which has limited efficacy in treating GISTs. Moreover, the identification of secondary mutations in KIT, which can confer resistance to imatinib, has prompted the development of second-line therapies such as sunitinib and regorafenib, further improving patient outcomes.

Another important molecular subtype is synovial sarcoma, characterized by the presence of the SS18-SSX fusion gene resulting from the t(X; 18) (p11; q11) chromosomal translocation. This fusion gene is present in more than 90% of synovial sarcomas and is considered a definitive diagnostic marker. The SS18-SSX fusion gene plays a crucial role in the pathogenesis of synovial sarcoma by altering chromatin remodeling and gene expression, leading to tumorigenesis. The identification of this fusion gene has enabled more accurate diagnosis, particularly in cases where histopathological features are ambiguous. Clinically, the presence of the SS18-SSX fusion gene has also been associated with prognosis. For instance, studies have suggested that the specific variant of the fusion gene (SSX1 vs. SSX2) may influence the clinical course, with some evidence indicating that the SS18-SSX2 variant is associated with a more favorable prognosis.

Ewing sarcoma is another STS subtype where molecular findings have had significant clinical implications. This tumor is defined by the presence of the EWSR1-FLI1 fusion gene, which results from the t(11; 22) (q24; q12) translocation. The EWSR1-FLI1 fusion gene is found in approximately 85% of Ewing sarcoma cases and serves as a critical diagnostic marker. This molecular alteration is not only essential for diagnosis but also for understanding the biology of the disease. The fusion protein acts as an aberrant transcription factor, driving the expression of genes that promote tumor growth and survival. The detection of the EWSR1-FLI1 fusion gene has facilitated early and accurate diagnosis, even in cases where the histological appearance is atypical. Additionally, research has shown that the type of EWSR1-FLI1 fusion (type 1 vs. type 2) may have prognostic significance, with type 1 fusions being associated with a better outcome. In addition to these well-known subtypes, molecular pathology has also uncovered distinct genetic profiles in other STS subtypes, such as liposarcomas. For instance, well-differentiated and dedifferentiated liposarcomas are characterized by the amplification of the MDM2 and CDK4 genes. These amplifications can be detected using fluorescence in situ hybridization (FISH) or polymerase chain reaction (PCR) and are crucial for distinguishing these tumors from benign lipomas, which do not exhibit these genetic changes. The clinical implications of this molecular distinction are significant, as it influences both the treatment approach and the prognosis. Patients with well-differentiated liposarcoma may benefit from surgical resection, while those with dedifferentiated liposarcoma, which has a higher risk of recurrence and metastasis, may require more aggressive treatment, including radiation or chemotherapy. Moreover, molecular subtyping has revealed the complexity and heterogeneity within STS subtypes, challenging the traditional classification systems. For example, recent

studies using next-generation sequencing (NGS) have identified a subset of leiomyosarcomas with alterations in the TP53 and RB1 genes, which are associated with a more aggressive clinical course and poorer prognosis. Similarly, undifferentiated pleomorphic sarcomas (UPS), which were once grouped together based on their histological appearance, have been shown to comprise multiple molecularly distinct entities. NGS has identified mutations in genes such as ATRX, NF1, and TP53 in these tumors, suggesting that they may represent a spectrum of diseases rather than a single entity. These findings have important implications for treatment, as they may lead to the development of more targeted therapies that address the specific genetic alterations present in each tumor. The clinical implications of molecular subtyping extend beyond diagnosis and treatment to include prognostication and the development of personalized medicine approaches. By identifying specific genetic alterations that are associated with particular outcomes, clinicians can better stratify patients based on their risk and tailor treatment accordingly. For instance, the presence of certain mutations may indicate a higher likelihood of recurrence or metastasis, prompting more aggressive treatment and closer monitoring. Conversely, the absence of high-risk genetic features may allow for less intensive treatment, reducing the risk of overtreatment and associated side effects. In conclusion, molecular subtyping of soft tissue sarcomas has revolutionized the field of oncology, providing critical insights into the diagnosis, classification, and management of these tumors. The identification of specific genetic alterations has enabled more precise and personalized treatment approaches, improving patient outcomes and advancing our understanding of the biology of STS. As molecular techniques continue to evolve, they will undoubtedly uncover even more intricate details of these complex tumors, further refining our ability to diagnose and treat STS in a manner that is tailored to the individual patient's molecular profile.

Conclusion

The advancements in molecular pathology have significantly transformed the landscape of soft tissue sarcoma (STS) diagnosis and classification. This paper has highlighted the critical role of molecular techniques-such as cytogenetic analysis, fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), and next-generation sequencing (NGS)-in enhancing the precision of STS diagnosis and providing a deeper understanding of the genetic underpinnings of these diverse malignancies. By identifying specific genetic alterations, these molecular tools have not only improved diagnostic accuracy but also paved the way for more personalized treatment strategies, ultimately leading to better patient outcomes. The integration of molecular pathology into clinical practice has allowed for the identification of key genetic markers that are pathognomonic for various STS subtypes, facilitating earlier and more accurate diagnosis. This, in turn, has informed therapeutic decisions, enabling the use of targeted therapies that are tailored to the molecular profile of the tumor. The ability to distinguish between morphologically similar but genetically distinct tumors has addressed many of the diagnostic challenges that previously plagued the management of STS, reducing the risk of misdiagnosis and inappropriate treatment. Furthermore, the molecular subtyping of STS has provided valuable prognostic information, allowing clinicians to stratify patients based on their risk and tailor treatment plans accordingly. The ongoing evolution of molecular techniques, particularly the advent of NGS, promises to further refine our understanding of the genetic landscape of STS, uncovering new therapeutic targets and offering hope for the development of novel treatments. In conclusion, molecular pathology has emerged as an indispensable tool in the diagnosis, classification, and management of soft tissue sarcomas. Its ability to provide precise, genetically-informed diagnoses has revolutionized the field, shifting the focus from traditional histopathology to a more comprehensive, molecularly-based approach. As research continues to advance, the integration of molecular insights into clinical practice will likely lead to even greater improvements in patient care, ushering in a new era of personalized medicine in the treatment of soft tissue sarcomas.

References

1. Fletcher CDM, Bridge JA, Hogendoorn P, Mertens F. WHO Classification of Tumours of Soft Tissue and Bone. 4th ed. Lyon: IARC Press; c2013.
2. Jo VY, Fletcher CD. WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition. Pathology. 2014;46(2):95-104.
3. Demetri GD, von Mehren M, Antonescu CR, *et al*. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr. Canc. Netw. 2010, 8(2)
4. Heinrich MC, Corless CL, Duensing A, *et al*. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299(5607):708-710.
5. Antonescu CR, Dal Cin P, Nafa K, *et al*. EWSR1-ETS fusion type predicts poor outcome in Ewing sarcoma/primitive neuroectodermal tumor: A report from the Children's Oncology Group. Cancer. 2006;106(7):1587-1594.
6. Ladanyi M, Bridge JA. Molecular pathology of soft tissue and bone tumors: A personal perspective. Histopathology. 2013;62(1):118-124.
7. Sandberg AA, Bridge JA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: synovial sarcoma. Cancer Genet Cytogenet. 2002;133(1):1-23.
8. Coindre JM, Hostein I, Maire G, *et al*. Inflammatory malignant fibrous histiocytomas and dedifferentiated liposarcomas: Clinicopathologic and molecular analysis of a series of 14 cases with MDM2 and CDK4 amplification. Am J Surg. Pathol. 2004;28(9):1257-1265.
9. Rubin BP, Antonescu CR. Genetic heterogeneity of soft tissue tumors and the implications for molecular diagnostics. J Mol Diagn. 2011;13(2):213-224.
10. Fisher C. The diversity of soft tissue tumours. Br J Cancer. 2004;91(6):1126-1130.
11. O'Sullivan B, Davis AM, Turcotte R, *et al*. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: A randomized trial. Lancet. 2002;359(9325):2235-2241.
12. Schaefer IM, Hornick JL, Fletcher CDM. Aggressive variants of well-differentiated liposarcoma. Mod Pathol. 2010;23(5):601-609.

13. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;23(2):70-83.
14. Italiano A, Di Mauro I, Rapp J, *et al*. Clinical effect of molecular subtypes in sarcoma patients treated with trabectedin within a compassionate use program. J Clin Oncol. 2014;32(18_suppl):10546-10546.
15. Dufresne A, Brahmi M, Karanian M, Blay JY. Molecular biology of sarcomas: State of the art and perspectives. Cancer Treat Rev. 2018;67:20-31.
16. van der Graaf WT, Blay JY, Chawla SP, *et al*. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879-1886.
17. Antonescu CR. The role of genetic testing in soft tissue sarcoma. Histopathology. 2006;48(1):13-21.